United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5) - sulfacetamide sodium 100 mg in 1 ml - sulfacetamide sodium ophthalmic solution usp, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: escherichia coli, staphylococcus aureus, streptococcus pneumoniae, streptococcus (viridans group), haemophilus influenzae, klebsiella species, and enterobacter species. topically applied sulfonamides do not provide adequate coverage against neisseria species, serratia marcescens and pseudomonas aeruginosa. a significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. sulfacetamide sodium ophthalmic solution is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute otitis media

United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - methocarbamol (unii: 125od7737x) (methocarbamol - unii:125od7737x) - methocarbamol 500 mg - methocarbamol tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. the mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. methocarbamol does not directly relax tense skeletal muscles in man. methocarbamol tablets are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin 3 mg in 1 ml - ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: staphylococcus aureus staphylococcus epidermidis enterobacter cloacae haemophilus influenzae proteus mirabilis pseudomonas aeruginosa staphylococcus aureus staphylococcus epidermidis streptococcus pneumoniae pseudomonas aeruginosa serratia marcescens* *efficacy for this organism was studied in fewer than 10 infections ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.

United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - naproxen sodium 550 mg - carefully consider the potential benefits and risks of naproxen sodium tablets, usp and other treatment options before deciding to use naproxen sodium tablets, usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient's weight. naproxen as naproxen sodium tablets are indicated: • for the relief of the signs and symptoms of rheumatoid arthritis • for the relief of the signs and symptoms of osteoarthritis • for the relief of the signs and symptoms of ankylosing spondylitis • for the relief of the signs and symptoms of juvenile arthritis • for relief of the signs and symptoms of tendonitis • for relief of the signs and symptoms of bursitis • for relief of the signs and symptoms of acute gout • for the management of pain • for the management of primary dysmenorrhea naproxen sodium tablets, usp are contrain

United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin ointment, 2% is indicated for the topical treatment of impetigo due to: staphylococcus aureus and streptococcus pyogenes . this drug is contraindicated in individuals with a history of sensitivity reactions to any of its components.

United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine hydrochloride 150 mg - ranitidine is indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out for 1 year. -

United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - doxycycline hyclate 100 mg - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections: -  rocky mountain spotted fever, typhus fever and the typhus group, q. fever, rickettsialpox, and tick fevers caused by rickettsiae. -  respiratory tract infections caused by mycoplasma pneumoniae. -  lymphogranuloma venereum caused by chlamydia trachomatis. -  psittacosis (ornithosis) caused by chlamydia psittaci. -  trachoma caused by chlamydia trachomatis, although the infectious agent is not always el

United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - chlorzoxazone (unii: h0de420u8g) (chlorzoxazone - unii:h0de420u8g) - chlorzoxazone tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. the mode of action of this drug has not been clearly identified, but may be related to its sedative properties. chlorzoxazone does not directly relax tense skeletal muscles in man. chlorzoxazone tablets are contraindicated in patients with known intolerance to the drug.

United States - English - NLM (National Library of Medicine)

keltman pharmaceuticals inc. - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - hydrocodone bitartrate 5 mg - hydrocodone bitartrate and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain. this product should not be administered to patients who have previously exhibited hypersensitivity to hydrocodone or acetaminophen. patients known to be hypersensitive to other opioids may exhibit cross-sensitivity to hydrocodone. hydrocodone bitartrate and acetaminophen tablets contain hydrocodone, an opioid agonist, and is a schedule iii controlled substance. hydrocodone bitartrate and acetaminophen tablets, and other opioids, used in analgesia can be abused and are subject to criminal diversion. addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. it is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. drug addiction is a treatable disease utilizing a multidisciplinary approach, bu